Moleculin Announces Reverse Stock Split
Moleculin Biotech filed a charter amendment to effect a 1-for-20 reverse stock split, effective at market open on October 20, 2026, under the existing ticker MBRX with a new CUSIP. Shares outstanding will drop from roughly 20.9 million to approximately 1.05 million, with cash paid in lieu of fractional shares; authorized shares stay at 500 million.
Key figures
- Par value
- $0.001
- Authorized shares
- 500 million
- Reverse split ratio
- 1-for-20
- Shares outstanding after
- approximately 1.05 million
- Shares outstanding before
- approximately 20.9 million
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.